BioNTech's pre-market trading for its U.S. stock sees a short-term decline, now down more than 12%. The company announced the termination of Phase 2 of its Cevumeran cancer immunotherapy trial; Moderna's pre-market decline has widened to over 4%. $MRNA yesterday mrna issued additional convertible bonds; I forgot to look at this stock— it should still fall. The mrna company will issue $2.0 billion in senior convertible notes.